1. Home
  2. Investing
  3. Stocks
  4. USA
  6. Blueprint Medicines Corporation (BPMC)
  7. Quote


Blueprint Medicines Stock Price

0.00 (0.0%)
Volume 0
Bid Price 98.07
Ask Price 107.23
News -
Day High


52 Week Range


Day Low
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Blueprint Medicines Corporation BPMC NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 102.52 04:03:50
Open Price Low Price High Price Close Price Prev Close
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 102.52 USD


Draw Mode:

Blueprint Medicines Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 6.01B 58.57M 58.21M $ 793.73M $ 326.07M 5.16 17.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -68.52k 1.70%

more financials information »

Blueprint Medicines News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BPMC Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week100.00105.8398.56102.24344,5822.522.52%
1 Month105.03106.2995.01100.74306,397-2.51-2.39%
3 Months87.32110.0885.2598.35353,02715.2017.41%
6 Months98.00110.0879.07591.09457,5454.524.61%
1 Year102.40125.6179.07596.99457,9470.120.12%
3 Years63.11125.6143.2980.29499,05139.4162.45%
5 Years32.68125.6125.0873.24464,06469.84213.71%

Blueprint Medicines Description

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Your Recent History
Blueprint ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.